Skip to content

Trial Summary

This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of MK-1308 when used in combination with pembrolizumab in participants with advanced solid tumors.

Acronym:

MK-1308-001

ACTRN/NCT /ethics:

NCT03179436

Scientific title:

A Phase 1 open-label, multi-arm, multicentre study of MK-1308 in combination with pembrolizumab for subjects with advanced solid tumours

Sponsor / Cooperative group:

Merck

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2017-07-02
Anticipated End Date2022-10-24

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Brian Stein
Recruitment StatusRecruiting